AGP Executive Report
Last update: 10 hours agoASCO Kidney Cancer: AI-augmented ctDNA tracking is spotlighted as a new way to sort prognostic risk in metastatic clear cell RCC, using serial tumor-informed blood tests to map how ctDNA kinetics shift with treatment. ASCO Prostate Cancer: A phase 2 radioligand approach pairs Ac-225 rosopatamab tetraxetan with PSMA targeting in Lu-PSMA–pretreated mCRPC, aiming for strong tumor uptake while limiting salivary gland and kidney exposure. SNMMI Imaging: First-in-human CD46 ImmunoPET (89Zr-DFO-YS5) targets prostate cancer lesions even when PSMA is absent, testing safety and lesion localization in mCRPC. Oncology Breakthroughs: Daraxonrasib shows major survival gains in previously treated pancreatic cancer, while Brukinsa (zanubrutinib) reports long-term CLL control at ASCO. Infection Prevention: PolyPid completes its FDA NDA for D-PLEX100 to prevent surgical site infections after colorectal surgery, backed by SHIELD II results. Public Health & Safety: A carbon monoxide leak was stopped at a Texas medical facility; separate reports warn about sepsis risk after Kyle Busch’s death. Access & Policy: Bangladesh signals universal health care in the next budget; AHA pushes a blueprint to cut costs and expand access. Digital Health/AI: World Bank targets 1.5B people reached by 2030 using AI-enabled health systems. Recall: Australia recalls Nature’s Own supplements over glass fragment risk.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
